Afkhami Farzaneh, Rostami Golriz, Peters Ove A, Kamalian Fardad
School of Dentistry, Tehran University of Medical Sciences, Mahan St, Tehran, 1894787545, Iran.
School of Dentistry, The University of Queensland, Brisbane, Australia.
Clin Oral Investig. 2023 Jul;27(7):3999-4006. doi: 10.1007/s00784-023-05025-y. Epub 2023 May 27.
This study aimed to compare the anesthetic efficacy of 1.8 mL (one cartridge) and 3.6 mL (two cartridges) buccal infiltration and buccal plus palatal infiltration of 4% articaine in maxillary first molar teeth with symptomatic irreversible pulpitis.
This randomized single-blind clinical trial was conducted on 45 patients with symptomatic irreversible pulpitis of maxillary first molars (Trial Registration No: IRCT2015011020238N2_2015). The patients were randomly divided into three groups (n = 15) for buccal infiltration of 1.8 mL articaine plus 1:100,000 epinephrine (group 1), buccal infiltration of 3.6 mL articaine (group 2), and buccal infiltration of 1.8 mL articaine plus palatal infiltration of 0.5 mL articaine (group 3). The pain intensity was measured by the Heft-Parker visual analog scale (VAS) during injection and during access cavity preparation. No pain or mild pain during treatment was considered as successful anesthesia. Data were analyzed by the Tukey's post hoc test.
The three groups had a significant difference in frequency of the perceived pain during injection (P = 0.01). A higher volume of 4% articaine and injection of articaine in both buccal and palatal sides provided a significantly higher anesthesia success rate (P = 0.049 and P < 0.01, respectively). The highest success rate was recorded in group 3 (93.33%) followed by group 2 (80%) and then group 1 (53.33%).
Increasing the administered volume of 4% articaine with 1:100,000 epinephrine and addition of palatal infiltration to buccal infiltration of articaine can significantly increase the success of anesthesia in maxillary first molars with symptomatic irreversible pulpitis.
Achieving deep anesthesia in teeth with irreversible pulpitis is a critical parameter in management of patients who are in urgent need of root canal treatments.
本研究旨在比较1.8毫升(一支)和3.6毫升(两支)4%阿替卡因颊侧浸润以及颊侧加腭侧浸润在上颌第一磨牙有症状不可逆性牙髓炎治疗中的麻醉效果。
本随机单盲临床试验对45例上颌第一磨牙有症状不可逆性牙髓炎患者进行(试验注册号:IRCT2015011020238N2_2015)。患者被随机分为三组(n = 15),分别为1.8毫升阿替卡因加1:100,000肾上腺素颊侧浸润(第1组)、3.6毫升阿替卡因颊侧浸润(第2组)、1.8毫升阿替卡因颊侧浸润加0.5毫升阿替卡因腭侧浸润(第3组)。在注射过程中和开髓准备过程中,采用Heft-Parker视觉模拟量表(VAS)测量疼痛强度。治疗过程中无疼痛或轻度疼痛视为麻醉成功。数据采用Tukey事后检验进行分析。
三组在注射时疼痛感知频率上有显著差异(P = 0.01)。较高剂量的4%阿替卡因以及在颊侧和腭侧同时注射阿替卡因,麻醉成功率显著更高(分别为P = 0.049和P < 0.01)。第3组成功率最高(93.33%),其次是第2组(80%),然后是第1组(53.33%)。
增加含1:100,000肾上腺素的4%阿替卡因给药量以及在阿替卡因颊侧浸润基础上加用腭侧浸润,可显著提高上颌第一磨牙有症状不可逆性牙髓炎麻醉的成功率。
在急需根管治疗的患者管理中,实现不可逆性牙髓炎牙齿的深度麻醉是一个关键参数。